Scarica l'app Stockscreener
52.40
1.76%
-0.94
Dopo l'orario di chiusura:
51.87
-0.53
-1.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$53.34
Aprire:
$54
Volume 24 ore:
15.77M
Relative Volume:
0.45
Capitalizzazione di mercato:
$11.29B
Reddito:
$1.78B
Utile/perdita netta:
$164.40M
Rapporto P/E:
75.94
EPS:
0.69
Flusso di cassa netto:
$236.51M
1 W Prestazione:
-2.09%
1M Prestazione:
+49.54%
6M Prestazione:
+62.63%
1 anno Prestazione:
+167.62%
Intervallo 1D:
$52.11
$55.00
Intervallo di 1 settimana:
$51.41
$56.30
Portata 52W:
$13.47
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Industria
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Confronta HIMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
52.40 | 11.98B | 1.78B | 164.40M | 236.51M | 0.69 |
|
PG
Procter Gamble Co
|
168.56 | 386.92B | 83.93B | 15.50B | 15.03B | 6.30 |
|
UL
Unilever Plc Adr
|
63.57 | 155.28B | 65.10B | 6.16B | 0 | 2.4569 |
|
CL
Colgate Palmolive Co
|
92.30 | 73.67B | 19.95B | 2.90B | 3.47B | 3.54 |
|
KMB
Kimberly Clark Corp
|
143.84 | 46.37B | 19.75B | 2.47B | 2.39B | 7.34 |
|
KVUE
Kenvue Inc
|
23.58 | 45.12B | 15.30B | 1.06B | 1.45B | 0.55 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy (NYSE:HIMS) - Seeking Alpha
HIMS: AI Advancements Set to Boost Direct-to-Consumer Value | HIMS Stock News - GuruFocus
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer - MSN
Is HIMS stock about to get 'Squid Game' treatment? - Investorsobserver
Why Hims & Hers Health Inc. (HIMS) Went Down On Tuesday - Insider Monkey
10 Stocks Got Wiped Out. Are You Holding Any? - Insider Monkey
SA analyst downgrades: NVDA, OKTA, HIMS, DDOG, WDAY, RNG - Seeking Alpha
3 Surprising Stocks That Have More Than Doubled in 2025 - AOL.com
3 Surprising Stocks That Have More Than Doubled in 2025 - The Motley Fool
Hims & Hers Health (HIMS) – Research Analysts’ Weekly Ratings Updates - Defense World
Medical Stocks To Watch Now – May 24th - Defense World
Hims & Hers Health (NYSE:HIMS) Trading Up 2.8% – Here’s What Happened - Defense World
Super Micro Computer, Hims & Hers And Aurora Innovation Are Among Top 10 Large-Cap Losers Last Week (May 19-May 23): Are The Others In Your Portfolio? - Benzinga
Hims & Hers Health: New Guidance Creates Huge Risk For Shorts (NYSE:HIMS) - Seeking Alpha
Why Hims & Hers Health Stock (HIMS) Is Too Hot to Handle - Yahoo Finance
‘Time to Choose Sides on HIMS Stock’ as Analysts Assign Mixed Ratings - The Globe and Mail
Mixed options sentiment in Hims and Hers Health with shares up 2.0% - TipRanks
HIMS Stock Sees Moderate Options Activity with Increased Downside Demand | HIMS Stock News - GuruFocus
Hims & Hers: Not The Dip I Want To Buy (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
Hims & Hers appoints Farshad Shadloo as VP of communications - Medical Marketing and Media
Hims & Hers Health and AST SpaceMobile have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
Validea Detailed Fundamental AnalysisHIMS - Nasdaq
When the Price of (HIMS) Talks, People Listen - news.stocktradersdaily.com
Hims Online Psychiatry 2025 Review - Everyday Health
Why Hims & Hers Health (HIMS) Stock Is Falling Today - Yahoo
Hims & Hers Introduces 6-Month Wegovy New Customer Offer - marketscreener.com
HIMS Launches Affordable Wegovy Access for Eligible Customers | - GuruFocus
Hims & Hers offers Wegovy at new accessible price By Investing.com - Investing.com India
HIMS Launches Affordable Wegovy Access for Eligible Customers | HIMS Stock News - GuruFocus
U.S. Markets Finished Mixed Thursday As Snowflake Led, Hims & Hers Health Lagged - Barron's
Hims & Hers offers Wegovy at new accessible price - Investing.com
Citi maintains Sell on Hims & Hers, holds $30 price target - Investing.com
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer - galvnews.com
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off? - MarketBeat
Hims & Hers Health Inc (HIMS) Stock Price Down 4.07% on May 22 - GuruFocus
Cigna’s $200 Weight-Loss Drug Cap Shakes Up Hims & Hers Stock - Wall Street Pit
Citi maintains sell rating on Hims & Hers with $30 target - Investing.com India
Hims & Hers Stock Drops After Evernorth Announces Cheaper Pricing For Weight-Loss Drugs: Retail’s Dull - MSN
Snowflake stock gains, Nvidia & Navitas, Hims & Hers slips - Yahoo Finance
HIMS Stock Declines by Over 10% Marking Significant Drop | HIMS - GuruFocus
Hims & Hers Health Stock Is Tumbling Thursday: What's Happening?Hims & Hers Health (NYSE:HIMS) - Benzinga
HIMS Stock Declines by Over 10% Marking Significant Drop | HIMS Stock News - GuruFocus
HIMS Stock Experiences Notable Decline | HIMS Stock News - GuruFocus
HIMS Shares Decline Following Evernorth Weight Loss Plan Announcement | HIMS Stock News - GuruFocus
Cigna to offer $200 Wegovy, Zepbound weight-loss benefit - Reuters
Up 157% in 2025, Is It Too Late to Buy Hims & Hers Stock? - AOL.com
Truist maintains Hims & Hers stock hold rating, $45 target By Investing.com - Investing.com Nigeria
Morgan Stanley maintains Hims & Hers stock with $40 target By Investing.com - Investing.com Nigeria
Morgan Stanley maintains Hims & Hers stock with $40 target - Investing.com
Hims & Hers Health: Stabilizing Growth and Cautious Revenue Guidance Lead to Hold Rating - TipRanks
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):